HomeCompareELEV vs FCPT

ELEV vs FCPT: Dividend Comparison 2026

ELEV yields 547.95% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ELEV wins by $125545.50M in total portfolio value
10 years
ELEV
ELEV
● Live price
547.95%
Share price
$0.37
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$125545.55M
Annual income
$92,380,482,230.31
Full ELEV calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — ELEV vs FCPT

📍 ELEV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodELEVFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ELEV + FCPT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ELEV pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ELEV
Annual income on $10K today (after 15% tax)
$46,575.34/yr
After 10yr DRIP, annual income (after tax)
$78,523,409,895.76/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, ELEV beats the other by $78,523,404,986.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ELEV + FCPT for your $10,000?

ELEV: 50%FCPT: 50%
100% FCPT50/50100% ELEV
Portfolio after 10yr
$62772.80M
Annual income
$46,190,244,002.79/yr
Blended yield
73.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

ELEV
Analyst Ratings
3
Buy
8
Hold
1
Sell
Consensus: Hold
Price Target
$9.00
+2365.8% upside vs current
Range: $8.00 — $10.00
Altman Z
-4.8
Piotroski
1/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ELEV buys
0
FCPT buys
0
No recent congressional trades found for ELEV or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricELEVFCPT
Forward yield547.95%6.05%
Annual dividend / share$2.00$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$125545.55M$49.1K
Annual income after 10y$92,380,482,230.31$5,775.28
Total dividends collected$122722.76M$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold
Analyst price target$9.00$27.00

Year-by-year: ELEV vs FCPT ($10,000, DRIP)

YearELEV PortfolioELEV Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$65,495$54,794.52$11,401$700.92+$54.1KELEV
2$405,475$335,396.34$13,064$864.84+$392.4KELEV
3$2,374,450$1,940,591.70$15,051$1,072.48+$2.36MELEV
4$13,161,259$10,620,596.57$17,442$1,337.22+$13.14MELEV
5$69,099,868$55,017,321.36$20,340$1,677.08+$69.08MELEV
6$343,894,398$269,957,539.26$23,880$2,116.57+$343.87MELEV
7$1,623,590,885$1,255,623,879.22$28,241$2,689.36+$1623.56MELEV
8$7,277,465,834$5,540,223,587.11$33,660$3,442.07+$7277.43MELEV
9$30,995,389,120$23,208,500,677.65$40,456$4,439.95+$30995.35MELEV
10$125,545,548,589$92,380,482,230.31$49,063$5,775.28+$125545.50MELEV

ELEV vs FCPT: Complete Analysis 2026

ELEVStock

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

Full ELEV Calculator →

FCPTREIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this ELEV vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ELEV vs SCHDELEV vs JEPIELEV vs OELEV vs KOELEV vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.